{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:46:39Z","timestamp":1790433999865,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00228-020-02963-4","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T10:02:42Z","timestamp":1595325762000},"page":"1623-1630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Inhibition of SARS-CoV-2 entry through the ACE2\/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2421-5677","authenticated-orcid":false,"given":"Georgia","family":"Ragia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-5469","authenticated-orcid":false,"given":"Vangelis G.","family":"Manolopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"issue":"6965","key":"2963_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426(6965):450\u2013454. https:\/\/doi.org\/10.1038\/nature02145","journal-title":"Nature."},{"issue":"8","key":"2963_CR2","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/sj.emboj.7600640","volume":"24","author":"W Li","year":"2005","unstructured":"Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M (2005) Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 24(8):1634\u20131643. https:\/\/doi.org\/10.1038\/sj.emboj.7600640","journal-title":"EMBO J"},{"issue":"2","key":"2963_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, M\u00fcller MA, Drosten C, P\u00f6hlmann S (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271\u2013280.e8. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052","journal-title":"Cell"},{"key":"2963_CR4","doi-asserted-by":"publisher","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.6019","DOI":"10.1001\/jama.2020.6019"},{"issue":"34","key":"2963_CR5","doi-asserted-by":"publisher","first-page":"30113","DOI":"10.1074\/jbc.M505111200","volume":"280","author":"DW Lambert","year":"2005","unstructured":"Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ (2005) Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280(34):30113\u201330119. https:\/\/doi.org\/10.1074\/jbc.M505111200","journal-title":"J Biol Chem"},{"issue":"2","key":"2963_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.febslet.2007.11.085","volume":"582","author":"DW Lambert","year":"2008","unstructured":"Lambert DW, Clarke NE, Hooper NM, Turner AJ (2008) Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett 582(2):385\u2013390. https:\/\/doi.org\/10.1016\/j.febslet.2007.11.085","journal-title":"FEBS Lett"},{"issue":"4","key":"2963_CR7","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46(4):586\u2013590. https:\/\/doi.org\/10.1007\/s00134-020-05985-9","journal-title":"Intensive Care Med"},{"issue":"22","key":"2963_CR8","doi-asserted-by":"publisher","first-page":"7988","DOI":"10.1073\/pnas.0409465102","volume":"102","author":"H Hofmann","year":"2005","unstructured":"Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, P\u00f6hlmann S (2005) Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A 102(22):7988\u20137993. https:\/\/doi.org\/10.1073\/pnas.0409465102","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2963_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","volume":"52","author":"M Haschke","year":"2013","unstructured":"Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Kr\u00e4henb\u00fchl S (2013) Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 52(9):783\u2013792. https:\/\/doi.org\/10.1007\/s40262-013-0072-7","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2963_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","volume":"21","author":"A Khan","year":"2017","unstructured":"Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, Hardes K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, Bayliffe AI, Lazaar AL (2017) A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care 21(1):234. https:\/\/doi.org\/10.1186\/s13054-017-1823-x","journal-title":"Crit Care"},{"issue":"20","key":"2963_CR11","doi-asserted-by":"publisher","first-page":"30399","DOI":"10.1016\/j.cell.2020.04.004","volume":"S0092-8674","author":"V Monteil","year":"2020","unstructured":"Monteil V, Kwon H, Prado P, Hagelkr\u00fcys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. S0092-8674(20):30399\u201330398. https:\/\/doi.org\/10.1016\/j.cell.2020.04.004","journal-title":"Cell."},{"key":"2963_CR12","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe G, Hochman JS (2020) Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med 382:2441\u20132448. https:\/\/doi.org\/10.1056\/NEJMoa2008975","journal-title":"N Engl J Med"},{"key":"2963_CR13","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G (2020) Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med 382:2431\u20132440. https:\/\/doi.org\/10.1056\/NEJMoa2006923","journal-title":"N Engl J Med"},{"key":"2963_CR14","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1056\/NEJMoa2007621","volume":"382","author":"MR Mehra","year":"2020","unstructured":"Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN (2020) Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 382:e102. https:\/\/doi.org\/10.1056\/NEJMoa2007621","journal-title":"N Engl J Med"},{"key":"2963_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","volume":"76","author":"G Yang","year":"2020","unstructured":"Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, Cai J, Yang R, Han J, Huang Y, He S (2020) Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study. Hypertension. 76:51\u201358. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15143","journal-title":"Hypertension."},{"key":"2963_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F (2020) Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov 6:14. https:\/\/doi.org\/10.1038\/s41421-020-0153-3","journal-title":"Cell Discov"},{"issue":"8","key":"2963_CR17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/ajh.2008.202","volume":"21","author":"TW Kurtz","year":"2008","unstructured":"Kurtz TW, Pravenec M (2008) Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system. Am J Hypertens 21(8):852\u2013859. https:\/\/doi.org\/10.1038\/ajh.2008.202","journal-title":"Am J Hypertens"},{"issue":"2","key":"2963_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1124\/pr.112.007278","volume":"65","author":"MC Michel","year":"2013","unstructured":"Michel MC, Foster C, Brunner HR, Liu L (2013) A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 65(2):809\u2013848. https:\/\/doi.org\/10.1124\/pr.112.007278","journal-title":"Pharmacol Rev"},{"issue":"2","key":"2963_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1600-079X.2004.00141.x","volume":"37","author":"E Soto-Vega","year":"2004","unstructured":"Soto-Vega E, Meza I, Ram\u00edrez-Rodr\u00edguez G, Benitez-King G (2004) Melatonin stimulates calmodulin phosphorylation by protein kinase C. J Pineal Res 37(2):98\u2013106. https:\/\/doi.org\/10.1111\/j.1600-079X.2004.00141.x","journal-title":"J Pineal Res"},{"key":"2963_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/978-3-642-70070-5_8","volume-title":"Calcium and cell physiology","author":"BD Roufogalis","year":"1985","unstructured":"Roufogalis BD (1985) Calmodulin antagonism. In: Marm\u00e9 D (ed) Calcium and cell physiology. Springer, Berlin, Heidelberg, pp 148\u2013169"},{"key":"2963_CR21","doi-asserted-by":"publisher","first-page":"117583","DOI":"10.1016\/j.lfs.2020.117583","volume":"250","author":"R Zhang","year":"2020","unstructured":"Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, Liu C, Reiter RJ (2020) COVID-19: melatonin as a potential adjuvant treatment. Life Sci 250:117583. https:\/\/doi.org\/10.1016\/j.lfs.2020.117583","journal-title":"Life Sci"},{"issue":"1","key":"2963_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0006-291x(84)91062-3","volume":"118","author":"HY Lam","year":"1984","unstructured":"Lam HY (1984) Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 118(1):27\u201332. https:\/\/doi.org\/10.1016\/0006-291x(84)91062-3","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2963_CR23","doi-asserted-by":"publisher","first-page":"e00765","DOI":"10.1128\/mBio.00765-13","volume":"5","author":"A Butts","year":"2014","unstructured":"Butts A, Koselny K, Chabrier-Rosell\u00f3 Y, Semighini CP, Brown JC, Wang X, Annadurai S, DiDone L, Tabroff J, Childers WE Jr, Abou-Gharbia M, Wellington M, Cardenas ME, Madhani HD, Heitman J, Krysan DJ (2014) Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. mBio 5(1):e00765\u2013e00713. https:\/\/doi.org\/10.1128\/mBio.00765-13","journal-title":"mBio"},{"issue":"8","key":"2963_CR24","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1128\/AAC.03036-14","volume":"58","author":"J Dyall","year":"2014","unstructured":"Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG Jr, Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB (2014) Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58(8):4885\u20134893. https:\/\/doi.org\/10.1128\/AAC.03036-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2963_CR25","doi-asserted-by":"publisher","first-page":"e02272","DOI":"10.1128\/mBio.02272-18","volume":"9","author":"MC Montoya","year":"2018","unstructured":"Montoya MC, Krysan DJ (2018) Repurposing estrogen receptor antagonists for the treatment of infectious disease. mBio 9(6):e02272\u2013e02218. https:\/\/doi.org\/10.1128\/mBio.02272-18","journal-title":"mBio"},{"key":"2963_CR26","unstructured":"Dompe.com. Press release. EU-supported private-public consortium Exscalate4CoV: raloxifene proposed for clinical trials after tests show it inhibits SARS-CoV-2. https:\/\/www.dompe.com\/en\/media\/press-releases. Accessed 3 July 2020"},{"issue":"14","key":"2963_CR27","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1177\/1535370217718808","volume":"242","author":"A Bukowska","year":"2017","unstructured":"Bukowska A, Spiller L, Wolke C, Lendeckel U, Weinert S, Hoffmann J, Bornfleth P, Kutschka I, Gardemann A, Isermann B, Goette A (2017) Protective regulation of the ACE2\/ACE gene expression by estrogen in human atrial tissue from elderly men. Exp Biol Med (Maywood) 242(14):1412\u20131423. https:\/\/doi.org\/10.1177\/1535370217718808","journal-title":"Exp Biol Med (Maywood)"},{"issue":"5","key":"2963_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1113\/expphysiol.2007.041806","volume":"93","author":"KB Brosnihan","year":"2008","unstructured":"Brosnihan KB, Hodgin JB, Smithies O, Maeda N, Gallagher P (2008) Tissue-specific regulation of ACE\/ACE2 and AT1\/AT2 receptor gene expression by oestrogen in apolipoprotein E\/oestrogen receptor-alpha knock-out mice. Exp Physiol 93(5):658\u2013664. https:\/\/doi.org\/10.1113\/expphysiol.2007.041806","journal-title":"Exp Physiol"},{"issue":"1","key":"2963_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.18433\/jpps31069","volume":"23","author":"Z Suba","year":"2020","unstructured":"Suba Z (2020) Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients. J Pharm Pharm Sci 23(1):75\u201385. https:\/\/doi.org\/10.18433\/jpps31069","journal-title":"J Pharm Pharm Sci"},{"key":"2963_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","volume":"116","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, P\u00f6hlmann S, McKerrow JH, Renslo AR, Simmons G (2015) Protease inhibitors targeting coronavirus and filovirus entry. Antivir Res 116:76\u201384. https:\/\/doi.org\/10.1016\/j.antiviral.2015.01.011","journal-title":"Antivir Res"},{"issue":"11","key":"2963_CR31","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1128\/AAC.01043-16","volume":"60","author":"M Yamamoto","year":"2016","unstructured":"Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue JI, Matsuda Z (2016) Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother 60(11):6532\u20136539. https:\/\/doi.org\/10.1128\/AAC.01043-16","journal-title":"Antimicrob Agents Chemother"},{"key":"2963_CR32","doi-asserted-by":"publisher","unstructured":"Hoffmann M, Schroeder S, Kleine-Weber H, M\u00fcller MA, Drosten C, P\u00f6hlmann S (2020) Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother AAC.00754\u201320. https:\/\/doi.org\/10.1128\/AAC.00754-20","DOI":"10.1128\/AAC.00754-20"},{"issue":"12","key":"2963_CR33","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1210\/me.2013-1098","volume":"27","author":"L Clinckemalie","year":"2013","unstructured":"Clinckemalie L, Spans L, Dubois V, Laurent M, Helsen C, Joniau S, Claessens F (2013) Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol Endocrinol 27(12):2028\u20132040. https:\/\/doi.org\/10.1210\/me.2013-1098","journal-title":"Mol Endocrinol"},{"key":"2963_CR34","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/jocd.13443","volume":"19","author":"A Goren","year":"2020","unstructured":"Goren A, Va\u00f1o-Galv\u00e1n S, Wambier CG, McCoy J, Gomez-Zubiaur A, Moreno-Arrones OM, Shapiro J, Sinclair RD, Gold MH, Kovacevic M, Mesinkovska NA, Goldust M, Washenik K (2020) A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain - a potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol 19:1545\u20131547. https:\/\/doi.org\/10.1111\/jocd.13443","journal-title":"J Cosmet Dermatol"},{"key":"2963_CR35","doi-asserted-by":"publisher","unstructured":"Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, Carbone GM, Cavalli A, Pagano F, Ragazzi E, Prayer-Galetti T, Alimonti A (2020) Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532). Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.479","DOI":"10.1016\/j.annonc.2020.04.479"},{"issue":"1","key":"2963_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1164\/rccm.202003-0821OC","volume":"202","author":"MC Peters","year":"2020","unstructured":"Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, Woodruff PG, Mauger DT, Erzurum SC, Johansson MW, Denlinger LC, Jarjour NN, Castro M, Hastie AT, Moore W, Ortega VE, Bleecker ER, Wenzel SE, Israel E, Levy BD, Seibold MA, Fahy JV (2020) COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 202(1):83\u201390. https:\/\/doi.org\/10.1164\/rccm.202003-0821OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"2963_CR37","doi-asserted-by":"publisher","first-page":"30730","DOI":"10.1016\/j.jaci.2020.05.013","volume":"S0091-6749","author":"P Bradding","year":"2020","unstructured":"Bradding P, Richardson M, Hinks TSC, Howarth PH, Choy DF, Arron JR, Wenzel SE, Siddiqui S (2020) ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma-implications for COVID-19. J Allergy Clin Immunol S0091-6749(20):30730\u201330732. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.013","journal-title":"J Allergy Clin Immunol"},{"key":"2963_CR38","unstructured":"Recoverytrial.net. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. https:\/\/www.recoverytrial.net\/news, published on June 16, 2020. Accessed 3 July 2020"},{"issue":"2","key":"2963_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/10409231003628015","volume":"45","author":"M Gooz","year":"2010","unstructured":"Gooz M (2010) ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 45(2):146\u2013169. https:\/\/doi.org\/10.3109\/10409231003628015","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2963_CR40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fphys.2016.00469","volume":"7","author":"J Xu","year":"2016","unstructured":"Xu J, Mukerjee S, Silva-Alves CR, Carvalho-Galv\u00e3o A, Cruz JC, Balarini CM, Braga VA, Lazartigues E, Fran\u00e7a-Silva MS (2016) A disintegrin and metalloprotease 17 in the cardiovascular and central nervous systems. Front Physiol 7:469. https:\/\/doi.org\/10.3389\/fphys.2016.00469","journal-title":"Front Physiol"},{"issue":"6","key":"2963_CR41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/cmi.2014.101","volume":"12","author":"J Ren","year":"2015","unstructured":"Ren J, Nie Y, Lv M, Shen S, Tang R, Xu Y, Hou Y, Zhao S, Wang T (2015) Estrogen upregulates MICA\/B expression in human non-small cell lung cancer through the regulation of ADAM17. Cell Mol Immunol 12(6):768\u2013776. https:\/\/doi.org\/10.1038\/cmi.2014.101","journal-title":"Cell Mol Immunol"},{"issue":"13","key":"2963_CR42","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-10-0014","volume":"16","author":"JN Kyula","year":"2010","unstructured":"Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG (2010) Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res 16(13):3378\u20133389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0014","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02963-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-02963-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02963-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T23:21:25Z","timestamp":1626823285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-02963-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2963"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02963-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"21 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}